Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABL1 | P00519 | 14/20 | 0.61 |
| ▸ | BCR | P11274 | 14/20 | 0.61 |
| ▸ | TNNI3K | Q59H18 | 1/20 | 0.58 |
| ▸ | PGR | P06401 | 2/20 | 0.51 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KIT | P10721 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4667528 | 0.86 | ABL1 (0.57) | ABL1BCRTNNI3K | |
| SCHEMBL4666197 | 0.85 | ABL1 (0.53) | ABL1BCRMAP2K4USP2ALDH1A1 | |
| SCHEMBL4665846 | 0.85 | BACE1 (0.59) | ABL1BCRTNNI3KPGRUSP2 | |
| SCHEMBL4098721 | 0.84 | NPY5R (0.57) | ABL1BCRTNNI3KPKMHTT | |
| SCHEMBL4663960 | 0.83 | ABL1 (0.57) | ABL1BCRTNNI3K | |
| SCHEMBL4667404 | 0.80 | ABL1 (0.56) | ABL1BCRPGRMAP2K4USP2 | |
| SCHEMBL4664333 | 0.78 | TP53 (0.49) | ABL1BCRTNNI3KUSP2ALDH1A1 | |
| SCHEMBL5863265 | 0.77 | ABL1 (0.69) | ABL1BCRTNNI3KUSP2MAPK1 | |
| SCHEMBL4104594 | 0.77 | CCNT1 (0.69) | ABL1BCRTNNI3K | |
| SCHEMBL4109389 | 0.77 | EGFR (0.54) | ABL1BCRTNNI3KUSP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | ALTANA PHARMA AG (DE) | 2008-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242681-A1 | N-4-(6-(Hetero)Aryl-Pyrimidin-4-Ylaminophenyl)-Benzenesulfonamides as Kinase Inhibitors | MAP3K19, MAP3K6, MAP3K20 | ABL1 24/4885BCR 402/4885TNNI3K 25/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.